INTRODUCTION
Women with early-stage breast cancer receive chemotherapy, endocrine therapy, or both to reduce recurrence and improve survival. The decision to undergo endocrine therapy depends on the presence of the estrogen receptor (ER), whereas the use of adjuvant chemotherapy depends largely on the patient's risk of recurrence. 1 Traditional factors used to determine recurrence risk are age, tumor size, grade, lymphovascular invasion, and axillary lymph node metastases.
In general, women with node-negative, ERpositive breast cancer are offered endocrine therapy and have an excellent prognosis. However, some have tumors that are likely to recur and could benefit from chemotherapy. No single test exists to determine with certainty whether the tumor will recur or not.
In the past decade, multigene expressionbased prognostic tests have been developed to aid in decision-making for early breast cancer. Oncotype DX (Genomic Health, Redwood City, CA) is a reverse-transcriptase polymerase chain reaction test based on the expression of 21 genes. It reports a recurrence score (RS), which is independently predictive of the risk of distant recurrence and, to a lesser degree, the responsiveness to chemotherapy of patients with node-negative, ER-positive breast cancer who are receiving tamoxifen or aromatase inhibitors. [2] [3] [4] The RS is used to assign patients with node-negative disease into low-, intermediate-, and high-risk groups. 2, 3 Oncotype DX was rapidly adopted in the United States despite limited evidence of its effectiveness. 5 No randomized trials had been conducted, and only small cohort studies were available to show that the RS influenced patients' preferences for chemotherapy and oncologists' recommendations for chemotherapy. 6 Economic studies showed that the test was cost saving, a finding that reflected a reduction in adjuvant chemotherapy use. 7, 8 The province of Ontario, Canada, has a publicly funded healthcare system. In 2010, the out-of-country branch of the Ontario Ministry of Health & Long-Term Care (OMHLTC) began funding Oncotype DX testing on a case-by-case basis by physician request. The Ontario Health Technology Assessment Committee recommended to the OMHLTC that the test be made available in Ontario as part of a field evaluation study. 9 We conducted a prospective cohort study of patients with node-negative, ER-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who were candidates for chemotherapy. The primary objective was to evaluate whether the RS changed oncologists' treatment recommendations and patients' treatment preferences.
PATIENTS AND METHODS

Patient Population
Inclusion criteria were histologic evidence of invasive breast cancer that was treated with surgical resection, that is, breast-conservation surgery, modified radical mastectomy, or simple mastectomy in the previous 4 months; axillary lymph nodes negative for cancer except for micrometastases, which was assessed by means of sentinel node biopsy, axillary lymph node dissection, or both; tumor that was ER positive; the patient receiving or intending to receive endocrine therapy; and the patient being considered for adjuvant chemotherapy. Exclusion criteria were inoperable, locally advanced, or metastatic breast cancer; previous neoadjuvant chemotherapy; an HER2-positive tumor; and a physician or patient unwilling to comply with the protocol.
The study was approved by the institutional review board of each participating center, and each patient provided informed consent. The Oncotype DX test was funded by the OMHLTC. Initially, selected centers participated in the study. All remaining sites in Ontario joined in a staggered fashion. After March 15, 2013, the date when all sites were activated, the Ministry would cover the cost of the test only if the patient was in the study.
Intervention
Eligible consenting patients were registered through the Ontario Clinical Oncology Group's Web-based registration system. Because the time taken to obtain ethics approval varied among institutional review boards, study sites joined at different times.
We chose to compare Oncotype DX with Adjuvant! Online (AOL) because AOL is freely available and is commonly used in clinics to help in decision-making by describing the risk of recurrence and mortality in patients with early-stage breast cancers who have undergone surgery. 10 The AOL risk estimates were continuous and were based on the age and tumor factors of the patient (size, grade, ER status, and axillary node involvement). AOL does not typically assign patients into low-, intermediate-, or high-risk groups. We used the method described by Bryant 11 to create three risk groups to compare Oncotype DX with AOL (Data Supplement).
Patients with nodal micrometastases were regarded as having a stage of N1 to N3 in the AOL recurrence estimate.
Patients underwent an initial consultation with their medical oncologist. In all cases, the physician or study nurse calculated the AOL before the oncologist went into the examining room. Patients were informed about their risk of recurrence or death with no therapy, with endocrine therapy, and with chemoendocrine therapy. The oncologist then used AOL results, as well as traditional pathology factors, to make a preliminary recommendation for endocrine therapy with chemotherapy, which was noted as yes; or without, noted as no; or unsure. Similarly, the patient was asked to state their preference for chemotherapy as yes, no, or unsure. Patients were asked to complete a questionnaire regarding satisfaction with their decision-making by using the 16-item decisional conflict scale (DCS). 12 After consultation, the patient's tumor sample was sent to Genomic Health, and after the RS was available, in approximately 2 weeks, the patient returned to discuss the final treatment choice. At that time, the patient and physician each made a decision regarding chemotherapy, noted as only a yes or no response. The final treatment recommendation of the oncologist and the treatment preference of the patient were documented. The patient again completed the DCS questionnaire. Finally, the specific therapy the patient received was documented.
Outcomes
The primary outcomes were the change in the oncologists' treatment recommendation and the change in patients' treatment preference. Secondary outcomes were the level of association between the RS with the estimated AOL recurrence risk, as well as with traditional factors including tumor size and grade, and the change in the level of the patient's decision conflict as measured in the DCS and subscales, that is, uncertainty, effective decision-making, and factors contributing to uncertainty.
Sample Size
Lo et al 6 showed that the treatment recommended by the physician changed in 23 of 89 (25.8%) patients. We estimated that, by including 1,000 patients in our study, we would have sufficient statistical power to allow accurate estimation within 6 2.8% of the true percentage of patients with a change resulting from the RS. Given the requests to the OMHLTC for Oncotype DX, we expected that 1,000 patients could be recruited within 1 year.
Analysis
Patient and tumor characteristics were summarized across all patients. Categorical variables were summarized as counts and percentages, and continuous measures were summarized as medians and ranges. They were also reported as categories where applicable (eg, age as 10-year intervals and tumor size as , 1, 1 to , 2, 2 to , 3, or $ 3 cm). The continuous RS and AOL scores were described by using histograms. Both scores were also categorized into three risk groups: low, intermediate, and high. For RS, the groupings were less than 18, 18 to 30, and $ 31, respectively. For AOL, the groupings were less than 26, 26 to 36 and $ 37, as described by Bryant.
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Tabulated for all patients were the primary outcomes, the oncologist's treatment recommendation, and the patient's treatment preference before the Oncotype DX test-with responses of yes, no, or unsure-and after knowledge of RS-with responses of yes or no. Results were subdivided according to RS and AOL risk-of-recurrence categories and by whether they ultimately received chemotherapy, which was recorded as yes or no. Agreement between the RS and AOL risk-of-recurrence estimates were calculated by using the Pearson correlation coefficient for continuous data and polychoric correlation for ordinal data. The association between RS category and grade, and between RS and tumor size categories, were assessed by using an exact nonparametric trend test 13 and a supportive analysis with continuous RS by using either a Pearson correlation or a oneway analysis of variance.
Responses on the DCS questionnaire were scored into an overall score and one score for each subscale, as recommended by O'Connor. 12 Change in mean response from pretest to post-test for each subscale and overall was analyzed by using paired t tests and linear regression. The effect of the RS on those who did or did not actually receive chemotherapy was analyzed by using unpaired t tests.
Agreement between patients' preferences and oncologists' recommendations pretest and post-test was summarized by using the Cohen k statistic. Proportions for unpaired data were compared by using x 2 and McNemar x 2 tests for paired data. P values # .05 were considered to indicate a statistically significant difference. Analyses were conducted by using SAS version 9.3 (Cary, NC) and StatXact version 9 (Cytel; Cambridge, MA). Table 1 .
RESULTS
Between January
Overall, 202 patients received chemotherapy, and 772 did not. Treatment in 26 was unknown; five withdrew consent, five were lost to follow up, one was later found to have stage IV disease, and 15 did not have an RS. The most common chemotherapy regimens were docetaxel-cyclophosphamide (n = 95), fluorouracil-epirubicin-cyclophosphamide followed by docetaxel (n = 44), and dose-dense adriamycin-cyclophosphamidepaclitaxel (n = 30).
RSs were not available on 21 patients; 16 had insufficient tumor material, and it was not obtained in five. Figure 1 shows the distribution of the 979 scores. According to the RS, 58% of patients were categorized as having low risk; 33%, as having intermediate risk; and 9%, as having high risk. The AOL RSs collected in all 1,000 patients are shown in the Data Supplement: 55%, 15%, and 31% were assigned to categories of low, intermediate, or high risk, respectively. A weak relationship was observed between the categories of tumor size and RS (P = .066; Data Supplement). However, the correlation between the raw scores was poor (r = 0.043). The relationship between tumor grade I, II, or III and RS category was strong (P , .001; Data Supplement). With RS as a continuous variable, the results from a single-factor analysis of variance by categories of grade was also highly significant (P , .001). None of the grade I tumors, 6% of grade II tumors, and 33% of grade III tumors had a high risk RS. Conversely, of the 92 patients with a high RS, 58 (63%) had grade III disease. The relationship between age as a continuous variable and RS was weak (r = 20.07).
Correlations between the RS and AOL scores were poor (Pearson r = 0.23; 95% CI, 0.17 to 0.29 and polychoric r = 0.26; 95% CI, 0.18 to 0.34). Of 530 patients deemed to have a low risk by using AOL, 349 (66%) had a low risk by using RS, 159 (30%) had an intermediate risk, and 22 (4%) were classified as having a high risk. Of the 151 patients classified as having an intermediate risk by using AOL, 41% had a low risk with RS, and 44% were at intermediate risk. Of the 298 patients at high-risk with AOL,16% had a high-risk RS (Table 2) . With regard to actual treatment (Table 3) , 79% of those classified as having high risk by using the RS received chemotherapy, whereas 31% of patients at high risk with AOL received chemotherapy (P , .001).
The primary outcome measure was the effect of the RS on the chemotherapy recommendation and actual treatment received (Table 4 ). In the 972 patients with complete data, oncologists' recommendations pretest and post-test were the same in 464 patients (48%), changed from unsure or chemotherapy to no Abbreviations: n/a, not available; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2. *Data are presented as median with range in parentheses.
www.jco.org chemotherapy in 365 (38%), and changed from unsure or no chemotherapy to chemotherapy in 143 (15%). For the 236 patients in whom oncologist post-test recommendation was chemotherapy, 190 (81%) actually received chemotherapy. For the 736 patients in whom the recommendation was no chemotherapy, 12 (2%) received chemotherapy. Results for patient preference for chemotherapy followed a similar pattern (Table 5) . However, more patients than physicians felt unsure pretest (42% v 34%; P ,.001).
Before Oncotype DX testing, the agreement between the patients' and physicians' responses for chemotherapy preference was poor (k = 0.17; 95% CI, 0.12 to 0.22). After knowing test results, their agreement in the 955 who responded was excellent (k = 0.80; 95% CI, 0.76 to 0.85).
Results for the 72 patients with micrometastases compared with those without micrometastases are shown in the Data Supplement.
The mean change in patients' DCS total score from pretest to post-test (Data Supplement) was reduced from 34 to 19 (P ,.001). Similar reductions were observed for the subscales of decisional uncertainty (P ,.001), factors affecting uncertainty (P ,.001), and effective decision making (P , .001). A statistically significant difference was observed in mean change scores for the DCS and the subscales between patients who chose chemotherapy and those who did not (Data Supplement).
DISCUSSION
RS influenced oncologists' treatment recommendations in about 50% of the patients. The major effect of the test was in the avoidance of chemotherapy in the clinical situation in which AOL showed high or intermediate risk.
Studies in which researchers evaluated the effect of Oncotype DX testing on decision making have varied in design and size. The study of 89 patients by Lo et al 6 involved oncologists from three academic practices and one community practice. Oncologists' treatment recommendations changed for 28 subjects (31.5%). In another study from two cancer centers in British Columbia, oncologists changed their recommendations in 45 (30%) of the 156 cases.
14 Carlson and Roth 15 systematically reviewed eight Oncotype DX studies. Overall, the test changed physicians' recommendations in 33.4% of patients. Inclusion of the unsure preference option is a unique aspect of our study compared with other studies. However, a participant's knowledge that their tumor would be sent for RS determination and that more information would be forthcoming may have contributed to the relatively high proportion of unsure responses at the pre-RS assessment. Offering patients and providers the unsure option may have led to an overestimate of the proportion of patients for whom the RS changed the chemotherapy decision. If we consider the pretest unsure responses as choices for chemotherapy or for no chemotherapy, the test would result in changes in 27% and 44% of patients, respectively. The middle of this range of percentages is about 35%, similar to results from studies in the literature.
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The patient's final decision for treatment and the oncologist's final recommendation agreed in 93% of cases. The low rate of agreement between the patient's initial decision and the physician's preliminary recommendation was likely a result of substantially more patients than physicians feeling unsure pretest.
Substantial reductions were observed in the DCS and its subscales between the pretest and post-test scores. The magnitude of the reductions exceeded what is considered to be the minimally clinically important difference for the instrument. 16 However, the fact patients were aware that the RS would be used to help make the decision likely contributed, at least in part, to these improvements. In addition, after a treatment plan is made, patients tend to feel less uncertain about the future.
Investigators using archived specimens from completed clinical trials demonstrated that the RS provided additional prognostic information compared with traditional factors.
2,4 Our study protocol mandated prospective collection of data regarding pathologic tumor characteristics. A strong association existed between RS and tumor grade. No grade I tumors had a high RS. Similarly, in a study from British Columbia, no high RS tumors were grade I. 17 In the study by Paik et al, 2 tumor grade was prognostic for distant recurrence and the RS was independently prognostic. Although an association was noted between histologic grade, and RS, only modest agreement existed among three pathologists who assessed the grade centrally. 3 Reasons for the difference between our results and those of the National Surgical Adjuvant Breast and Bowel Project study were that we excluded patients with HER2 tumors and laboratory quality-control measures have been implemented across Ontario to standardize pathologic assessment, including ER, progesterone-receptor, and HER2 testing.
The rising cost of healthcare is a challenge for healthcare systems. 18 Oncotype DX is expensive. Data from our study suggest that tumor grade might serve as a guide in the selection of patients for whom the test can be avoided; for example, when chemotherapy would be added only if the RS were high or the use of histopathologic markers to predict the RS category to shift RS testing from high-and low-risk cases to those of uncertain risk.
19-21
We chose to include patients with nodal micrometastases, because no Oncotype DX information was available for this subgroup when we started our study. Although the number of patients in this group was relatively small, the results appeared to be similar to those of patients with node-negative disease.
In any evaluation, the ability to generalize results depends on whether the population evaluated is similar to a readers' own patients. All patients with node-negative, ER-positive breast cancer in Ontario for whom an Oncotype DX test was ordered participated in our study. However, not all patients with node-negative, ER-positive disease in Ontario were included because clinicians had the option of selecting high-risk patients for chemotherapy, such as those with large, high-grade, or PR-negative tumors, or low risk patients for endocrine therapy alone. Therefore, it is conceivable that an element of selection was present in our study. Published reports of Oncotype DX testing are shown in the Data Supplement. The percentage of patients determined to be at high risk by means of the Oncotype DX test ranged from 9% in our study to 27% in the study by Paik et al. 2 The differences in rates between cohorts can be accounted for by differences in study design and patient selection. Based on postmarketing data in more than 20,000 patients, the percentage with a high RS was 15%. 22 The authors suggested that the shift in RS results from the study by Paik et al 2 reflected patient selection when the test was introduced into practice. Our study is one of the largest prospective studies to evaluate Oncotype DX in a general population. Study procedures and the collection of outcomes were standardized. Compliance with study procedures was good. Patients' preferences for chemotherapy and chemotherapy actually received were documented. The Ontario healthcare system facilitated the conduct of our study by covering the cost of the test only if the patient was part of the cohort study. However, our study was limited, as are others, by the lack of longterm patient follow-up. Although the Oncotype DX test changed physicians' recommendations, whether they made the correct decision is unknown. The ideal study design for evaluating the utility of a test such as Oncotype DX is a randomized trial in which investigators compare the new test with the usual test. The challenge is that such trials require many patients, involve lengthy follow-up, and are expensive. The results of the TAILORx, 26 OPTIMA, 27 and RxPONDER 28 randomized trials to evaluate the Oncotype DX test are eagerly anticipated. However, our study provides useful information regarding the role of this test in decision-making.
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